Evidence map›Paper›PMID 35910248›Full record

ArticleFrontiers in cellular neuroscience2022

Increased Serum NSE and S100B Indicate Neuronal and Glial Alterations in Subjects Under 71 Years With Mild Neurocognitive Disorder/Mild Cognitive Impairment.

Maryna Polyakova, Karsten Mueller, Katrin Arelin, Leonie Lampe, Francisca S Rodriguez, Tobias Luck, Jürgen Kratzsch, Karl-Titus Hoffmann, Steffi Riedel-Heller, Arno Villringer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Maryna PolyakovaMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Karsten MuellerMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Katrin ArelinMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Leonie LampeMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Francisca S RodriguezLIFE-Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Tobias LuckLIFE-Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Jürgen KratzschLIFE-Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Karl-Titus HoffmannInstitute of Neuroradiology, University Clinic, Leipzig, Germany.
Steffi Riedel-HellerLIFE-Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Arno VillringerMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Peter SchoenknechtLIFE-Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany.
Matthias L SchroeterMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Leipzig University · DEMax Planck Institute for Human Cognitive and Brain Sciences · DEGerman Center for Neurodegenerative Diseases · DEUniversity Hospital Leipzig · DEUniversity of Applied Sciences Erfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mild cognitive impairment (MCI) is considered a pre-stage of different dementia syndromes. Despite diagnostic criteria refined by DSM-5 and a new term for MCI - "mild neurocognitive disorder" (mild NCD) - this diagnosis is still based on clinical criteria. Methods: To link mild NCD to the underlying pathophysiology we assessed the degree of white matter hyperintensities (WMH) in the brain and peripheral biomarkers for neuronal integrity (neuron-specific enolase, NSE), plasticity (brain-derived neurotrophic factor, BDNF), and glial function (S100B) in 158 community-dwelling subjects with mild NCD and 82 healthy controls. All participants (63-79 years old) were selected from the Leipzig-population-based study of adults (LIFE). Results: Serum S100B levels were increased in mild NCD in comparison to controls ( Conclusion: Our findings might indicate the presence of neuronal (NSE) and glial (S100B) injury in mild NCD. Future studies need to investigate whether younger subjects with mild NCD with increased biomarker levels are at risk of developing major NCD.

Indexed as

BDNFBrain-Derived Neurotrophic Factormild cognitive impairmentneuron-specific enolaseNSES100Bwhite matter hyperintensities

Identifiers

PMID35910248
PMCPMC9329528
OpenAlexW4285386467

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.